BioSpace News Archive

Spine Align, LLC, a medical device company developing a portfolio of products that enable spine surgeons to measure, visualize, and adjust patients’ spinal alignment during surgery, recently closed a $1.75M Series Seed round.

Key opinion leaders are supporting the rollout of DXRX, the world’s first diagnostic network for precision medicine Group of global experts have more than 120 years of collective experience in precision medicine testing

A validation study highlighting the reliability and ease of use of the Infantile Hemangioma Referral Score (IHReS) for the early diagnosis, referral and treatment of infantile hemangioma (IH) was published recently in Pediatrics, as reported by Pierre Fabre Pharmaceuticals USA, Inc.

Locanabio, Inc., a leader in RNA-targeted gene therapy, today announced that results from a preclinical study of the company’s therapeutic systems for the potential treatment of myotonic dystrophy type 1 (DM1) were published in Nature Biomedical Engineering.

Cyxone (publ), a Swedish biotech company dedicated to developing improved treatments for autoimmune diseases, announces today that it plans to initiate a phase 2 clinical trial with Rabeximod in Covid-19 patients.

RLDatix, the leading global provider of intelligent patient safety solutions, announced today that it has acquired oneSOURCE, the leading healthcare medical equipment SaaS database that provides online access to continuously-updated instructions for use (IFU) and preventative maintenance documentation.

Rejoni announced today that it has closed a $15 million Series A financing. The round was led by Ascension Ventures, with additional participation from Delos Capital and Sparta Group.

Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced that it has received CE mark for its first product, the BioBridge® Collagen Matrix. BioBridge is classified as a Class III device with an indication for use to support lymphatic tissue repair and can be used after or in conjunction

AllStar Health Brands Inc. a specialty pharmaceutical and nutritional supplements company Provides Updates on its Operations.

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of John G. Houston, Ph.D., to its board of directors as of September 10, 2020.